,PageNo,Text
0,page_1,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Principal Investigator: Benjamin Maughan, MD, PharmD', 'HUNTSMAN', 'CANCER INSTITUTE', 'UNIVERSITY OF UTAH', 'ACADEMIC: A Randomized Phase II Clinical Trial of ADT', 'Combined with Abiraterone or Docetaxel in Metastatic Hormone', 'Sensitive Prostate Cancer', 'HCI-18-GU-11/Trial ID: HCI115099', 'Coordinating Center', 'Huntsman Cancer Institute', 'Principal Investigator', 'Benjamin L. Maughan MD, PharmD', 'Huntsman Cancer Institute', 'University of Utah', '2000 Circle of Hope', 'Salt Lake City, Utah 84112', 'Email: benjamin.maughan@hci.utah.edu', 'Co-Investigators', 'Abhishek Tripathi MD', 'Stephenson Cancer Center', 'Oklahoma State University', 'Mehmet Bilen MD', 'Winship Cancer Institute', 'Emory University', 'Statistician(s)', 'Ken Boucher, PhD', 'Huntsman Cancer Institute - University of Utah', '2000 Circle of Hope Room 1710', 'Email: Ken.Boucher@hci.utah.edu', 'Medical Monitor', 'TBD', 'Coordinating Center Site', 'Please contact your assigned Clinical Site Monitor and', 'Contact', 'the Clinical Trials Compliance Office', '2000 Circle of Hope', 'Salt Lake City, UT 84112', 'compliance@hci.utah.edu', 'Commercial agents', 'Abiraterone Acetate (Zytiga, Yonsa, or generic),', 'Docetaxel (Taxotere)', 'IND Number', 'N/A', 'NCT Number (CT.gov)', 'NCT03827473', 'Historical Protocol Version Dates', 'Version 1: 09OCT2018', 'Version 2: 13MAR2019']"
1,page_2,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'TABLE OF CONTENTS', 'Page', 'LIST OF ABBREVIATION', '4', 'PROTOCOL SIGNATURE', '7', 'STUDY SUMMARY', '8', 'SCHEMA', '10', '1', 'OBJECTIVES', '11', '1.1', 'Primary Objective', 'Error! Bookmark not defined.', '1.2', 'Secondary Objectives', '11', '1.3', 'Exploratory Objectives', '11', '2', 'BACKGROUND', '12', '2.1', 'Hypothesis', '12', '3', 'DRUG INFORMATION', '13', '3.1', 'Androgen Deprivation Therapy', '13', '3.2', 'Docetaxel (Taxotere)', '13', '3.3', 'Abiraterone Acetate (Abiraterone)', '15', '4', 'STUDY DESIGN', '19', '4.1', 'Description', '19', '4.2', 'Number of Patients', '19', '4.3', 'Number of Study Centers', '19', '4.4', 'Study Duration', '19', '5', 'ELIGIBILITY CRITERIA', '20', '5.1', 'Inclusion Criteria', '20', '5.2', 'Exclusion Criteria', '21', '5.3', 'Recruitment Strategies', '23', '6', 'RANDOMIZATION', '23', '7', 'TREATMENT PLAN', '23', '7.1', 'Administration Schedule', '23', '7.2', 'Docetaxel', '23', '7.3', 'Zytiga (Abiraterone)', '24', '7.4', 'Concomitant Medications and Therapies', '24', '7.5', 'Duration of Therapy', '25', '8', 'TOXICITIES AND DOSEAGE MODIFICATION', '26', '8.1', 'Dose Modifications and Guidelines for Adverse Event Management', '26', '8.2', 'Supportive Care', '26', '8.3', 'Contraception', '26', '9', 'STUDY CALENDAR', '28', '10', 'STUDY PROCEDURES', '30', '10.1', 'Screening Evaluations', '30', '10.2', 'On Treatment Evaluations', '30', '10.2.2', 'At the time of Progression, if prior to M18 visit', '31', '11', 'CRITERIA FOR EVALUATION AND ENDPOINT', '31', '11.1', 'Safety', '31', '11.2', 'Efficacy', '31', '12', 'STATISTICAL CONSIDERATIONS', '32', 'Page 2 of 52']"
2,page_3,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '12.1', 'Primary Objective and Endpoint', '32', '12.2', 'Statistical Hypothesis', '32', '12.3', 'Secondary Objective and Endpoint', '32', '12.4', 'Sample Size Determination', '32', '12.5', 'Statistical Methods', '32', '13', 'REGISTRATION GUIDELINES', '33', '14', 'DATA SUBMISSION SCHEDULE', '33', '15', 'SPECIAL INSTRUCTIONS', '34', '15.1', 'Correlative Studies', '34', '16', 'ETHICAL AND REGULATORY CONSIDERATIONS', '35', '16.1', 'Informed consent', '35', '16.2', 'Institutional Review', '35', '16.3', 'SAE Reporting Requirements', '38', '16.4', 'Reporting of Pregnancy', '38', '16.5', 'Protocol Amendments', '38', '16.6', 'Protocol Deviations', '38', '16.7', 'FDA Annual Reporting', '39', '16.8', 'Clinical Trials Data Bank', '39', '16.9', 'Record Keeping', '39', '17', 'BIBLIOGRAPHY', '40', 'Appendix A: FACIT Administration Guidelines', '42', 'Appendix B: FACT-P', '43', 'Appendix C: FACT/GOG - NTX', '46', 'Appendix E: ECOG/KPS Conversion Table', '48', 'Appendix F: Overall Treatment Utility Form', '49', 'Appendix G: Was It Worth It Questionnaire', '50', 'Appendix H: End of Study Evaluation Form', '51', 'Page 3 of 52']"
3,page_4,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'LIST OF ABBREVIATION', 'Abbreviation or Term¹', 'Definition/Explanation', 'AE', 'Adverse event', 'ALT', 'Alanine aminotransferase', 'ANCOVA', 'Analysis of covariance', 'ANOVA', 'Analysis of variance', 'APTT', 'Activated partial thromboplastin time', 'AST', 'Aspartate aminotransferase', 'AV', 'Atrioventricular', 'B-HCG', 'Beta-human chorionic gonadotropin', 'BID', 'Twice daily', 'BLQ', 'Below limit of quantification', 'BMI', 'Body mass index', 'BP', 'Blood pressure', 'BUN', 'Blood urea nitrogen', 'Ca++', 'Calcium', 'CBC', 'Complete blood count', 'CFR', 'Code of Federal Regulations', 'CHF', 'Congestive heart failure', 'CI', 'Confidence interval', 'Cl-', 'Chloride', 'CLcr', 'Creatinine clearance', 'Cmax', 'Maximum observed concentration', 'Cmin', 'Trough observed concentration', 'CNS', 'Central nervous system', 'CR', 'Complete response', 'CRF', 'Case report form', 'CT', 'Computed tomography', 'CTCAE', 'Common Toxicity Criteria for Adverse Events', 'CV', 'Coefficient of variation', 'CYP', 'Cytochrome P450', 'D/C', 'Discontinue', 'ECOG', 'Eastern Cooperative Oncology Group', 'eCRF', 'Electronic case report form', 'DLT', 'Dose Limiting Toxicity', 'ECG', 'Electrocardiogram', 'Eg', 'Exempli gratia (for example)', 'FACS', 'Fluorescence Activated Cell Sorting', 'FDA', 'Food and Drug Administration', 'Page 4 of 52']"
4,page_5,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Abbreviation or Term¹', 'Definition/Explanation', 'FDG-PET', 'Fluorodeoxyglucose (FDG)-positron emission tomography (PET)', 'GCP', 'Good Clinical Practice', 'GFR', 'Glomerular filtration rate', 'GGT', 'Gamma glutamyl transferase', 'GLP', 'Good laboratory practice', 'HBsAg', 'Hepatitis B surface antigen', 'HBV', 'Hepatitis B virus', 'HCO3°', 'Bicarbonate', 'HCV', 'Hepatitis C virus', 'HIV', 'Human immunodeficiency virus', 'HR', 'Heart rate', 'hr', 'Hour or hours', 'IC50', 'Half maximal inhibitory concentration', 'i.e.', 'Id est (that is)', 'IEC', 'Independent ethics committee', 'IND', 'Investigational New Drug', 'INR', 'International normalized ratio', 'IRB', 'Institutional review board', 'IU', 'International unit', 'IV', 'Intravenous, intravenously', 'LDH', 'Lactate dehydrogenase', 'LHRH', 'Luteinizing hormone releasing hormone', 'LLQ', 'Lower limit of quantitation', 'MedRA', 'Medical Dictionary for Drug Regulatory Activities', 'MRI', 'Magnetic resonance imaging', 'MRSD', 'Maximum recommended starting dose', 'MTD', 'Maximum tolerated dose', 'NOAEL', 'No-observed-adverse-effect level', 'NOEL', 'No-observed-effect-level', 'PD', 'Pharmacodynamic(s)', 'PFS', 'Progression Free Survival', 'PK', 'Pharmacokinetic(s)', 'PO', 'Per os (administered by mouth)', 'PR', 'Partial response', 'PT', 'Prothrombin time', 'PTT', 'Partial thromboplastin time', 'QC', 'Quality control', 'RBC', 'Red blood cell', 'Page 5 of 52']"
5,page_6,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Abbreviation or Term¹', 'Definition/Explanation', 'QD', 'Once daily', 'QTc', 'QT interval corrected', 'QTcF', 'QT interval corrected using Frederichia equation', 'SAE', 'Serious adverse event', 'SD', 'Standard deviation or stable disease', 'T12', 'Terminal elimination half-life', 'T3', 'Triiodothyronine', 'T4', 'Thyroxine', 'Tmax', 'Time of maximum observed concentration', 'TID', 'Three times daily', 'TSH', 'Thyroid-stimulating hormone', 'ULN', 'Upper limit of normal', 'ULQ', 'Upper limit of quantitation', 'UV', 'Ultraviolet', 'WBC', 'White blood cell', 'WOCBP', 'Women of childbearing potential', 'WONCBP', 'Women of nonchildbearing potential', '1', 'All of these abbreviations may or may not be used in protocol.', 'Page 6 of 52']"
6,page_7,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'PROTOCOL SIGNATURE', 'I confirm that I have read this protocol, and I will conduct the study as outlined herein and', 'according to the ethical principles stated in the latest version of the Declaration of Helsinki, the', 'applicable ICH guidelines for good clinical practice, and the applicable laws and regulations of the', 'federal government. I will promptly submit the protocol to the IRB for review and approval. Once', 'the protocol has been approved by the IRB, I understand that any modifications made during the', 'study must first be approved by the IRB prior to implementation except when such modification', 'is made to remove an immediate hazard to the subject.', 'I will provide copies of the protocol and all pertinent information to all individuals responsible to', 'me who assist in the conduct of this study. I will discuss this material with them to ensure that they', 'are fully informed regarding the study treatment, the conduct of the study, and the obligations of', 'confidentiality.', 'This document is signed electronically through submission and approval by the Principal', 'Investigator at Huntsman Cancer Institute in the University of Utah IRB Electronic Research', 'Integrity and Compliance Administration (ERICA) system. For this reason, the Principal', 'Investigator at Huntsman Cancer Institute will not have a hand-written signature on this signature', 'page.', 'Instructions to multi-site Principal Investigators at locations other than Huntsman Cancer Institute:', 'SIGN and DATE this signature page and PRINT your name. Return the original, completed and', 'signed, to the HCI Research Compliance Office. Retain a copy in the regulatory binder.', 'Signature of Principal Investigator', 'Date', 'Principal Investigator Name (Print)', 'Name of Institution', 'Page 7 of 52']"
7,page_8,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'STUDY SUMMARY', 'Title', 'A Randomized Phase II Clinical Trial of ADT', 'Combined with Abiraterone or Docetaxel in', 'Metastatic Hormone Sensitive Prostate Cancer.', 'Short Title', 'ACADEMIC', 'Protocol Identifiers (IRB - internal)', 'IRB 115099 - HCI-18-GU-11', 'IND number', 'Exempt', 'Phase', 'Phase II', 'Design', 'This is an open label, randomized prospective', 'study of ADT + Abiraterone vs. ADT +', 'Docetaxel in men with metastatic hormone', 'sensitive prostate cancer.', 'Study Duration', 'This study is expected to enroll for 24 months.', 'Patients will be followed for 18 months or until', 'disease progression, whichever occurs first. It', 'will take approximately 3.5 years to complete', 'the study.', 'Study Center(s)', 'This will be a multi-institution trial conducted at', 'the Huntsman Cancer Institute, at the University', 'of Utah. Up to 7 additional centers may be', 'opened.', 'Objectives', 'The primary objective of this study is to assess', 'the difference in QOL from baseline to month', '12 between ADT + Docetaxel vs ADT +', 'Abiraterone.', 'Number of Subjects', '89 patients will be enrolled. Patients will be', 'randomized 1:1 to each treatment arm.', 'Diagnosis and Main Eligibility Criteria', '- Male subject aged > 18 years.', '- Histologically diagnosed adenocarcinoma of', 'the prostate by WHO.', '- Radiographically confirmed metastatic disease', 'prior to patient enrollment. Metastatic disease', 'can be confirmed based on conventional', 'imaging (CT, MRI, nuclear medicine bone scan)', 'or molecular imaging (fluciclovine-PET/CT', 'PSMA-PET/CT, Choline-PET/CT etc).', '- ECOG 2.', '- Prior therapy with ADT or first generation', 'anti-androgen receptor therapy (example:', 'bicalutamide) is allowed.', '- Prior abiraterone or docetaxel use for', 'metastatic hormone sensitive prostate cancer is', 'not allowed.', 'Page 8 of 52']"
8,page_9,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '- Completed any hormone therapy for localized', 'prostate cancer and testosterone has recovered.', '- Patients must not have a histologic diagnosis of', 'small cell prostate cancer or pure squamous cell', 'prostate cancer.', 'Study Product, Dose, Route, Regimen,', 'All patients will be treated with ongoing', 'Duration of administration', 'standard of care ADT (surgical or medical', 'castration, documented testosterone should be <', '50 ng/dL while on study.)', 'Arm A: ADT + 75mg/m2 Docetaxel IV', 'Q3weeks X 6 cycles.', 'Arm B: ADT + Abiraterone PO continuous until', 'disease progression.', 'Statistical Methodology', 'Statistical analysis will be performed in', 'collaboration with HCI biostatistical support and', 'use descriptive statistics as well as the Kaplan-', 'Meier estimates and the log-rank test.', 'Page 9 of 52']"
9,page_10,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Principal Investigator: Benjamin Maughan, MD, PharmD', 'HUNTSMAN', 'CANCER INSTITUTE', 'UNIVERSITY OF UTAH', 'SCHEMA', 'Key Eligibility:', 'Metastatic', 'adenocarcinoma of the', 'prostate', 'Arm A:', 'ECOG < 2', ""Physician's"", 'Testosterone recovery', 'choice ADT +', 'from systemic hormone', 'Docetaxel', 'therapy for localized', 'prostate cancer', 'Screening', 'Arm B:', ""Physician's"", 'Stratification:', 'choice ADT +', 'Gleason score', 'Abiraterone', 'Visceral metastasis', 'presence']"
10,page_11,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Principal Investigator: Benjamin Maughan, MD, PharmD', 'HUNTSMAN', 'CANCER INSTITUTE', 'UNIVERSITY OF UTAH', '1', 'OBJECTIVES', '1.1', 'Primary Objective', 'To assess the impact of abiraterone and docetaxel on total quality of life between screening', 'and month 12 of the study.', 'Primary Endpoint: The FACT-P questionnaire will be administered at baseline and month 12.', 'Total Scores will be quantified and compared between treatment arms.', '1.2', 'Secondary Objectives', '1. To assess PSA response rates across the entire population and compared between groups.', 'Secondary Endpoint: PSA evaluations will occur every 3 months while on study. The', 'Prostate Cancer Working Group 3 criteria (PCWG3) will be used to define PSA response', 'rates of 50% and 90% reductions.', '2. To assess impact of abiraterone and docetaxel on additional quality of life measurements', 'and quality of life trends throughout the duration of the study.', 'Secondary Endpoint: Patient reported questionnaires-including FACT-P, FACT/GOG-', 'NTX, and PROMIS Fatigue-will be administered at baseline and months 3, 6, 9, 12, and', '18. Total scores, subscale scores, and trends will be analyzed.', '3. To assess the potential clinical efficacy between treatment groups.', 'Secondary Endpoint: To assess the PSA progression free survival (PSA-PFS) between', 'treatment arms. PSA-PFS is defined based on PCWG3 criteria.', '1.3', 'Exploratory Objectives', '1. To assess biomarkers that may predict treatment response to hormonal therapy versus', 'chemotherapy. Changes to tumor suppressors and the androgen receptor as well as other', 'mechanisms will be analyzed from urine, blood and tumor tissue molecular analysis.', 'Exploratory Endpoint: Patients will have tissue collected during this study for correlative', 'analysis. Blood will be collected at baseline, and months 3, 6, and 18. Also, archival tissue', 'will be collected (if available) as well as an optional soft-tissue biopsy at the time of disease', 'progression.', '2. To assess additional measures of overall quality of life between groups.', 'Exploratory Endpoint: The Overall Treatment Utility (OTU) form, Was It Worth It (WIWI)', 'questionnaire, and End of Study Evaluation Form will be administered to patients for', 'exploratory purposes. The OTU form should be completed by the treating physician at the', ""patient's 3 month visit and the WIWI questionnaire and End of Study Evaluation Form"", 'administered to the patient at the end of treatment (month 18 or progression visit,', 'whichever comes first).']"
11,page_12,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '2', 'BACKGROUND', '2.1', 'Hypothesis', 'Currently there are two competing standards of care for first-line treatment of patients with', 'metastatic hormone sensitive prostate cancer (mHSPC), with docetaxel plus ADT and', 'abiraterone plus ADT both demonstrating improved disease control over ADT alone. No direct', 'comparisons have been done between these therapies, so the optimal treatment for these', 'patients is currently not clear.', 'The first studies published to demonstrate improved overall survival over monotherapy of', 'androgen deprivation therapy (ADT) alone were the CHAARTED and STAMPEDE² (arms', 'A, B, C and E) prospective clinical trials. In the CHAARTED study, 790 patients were', 'randomized to ADT alone versus ADT plus 6 cycles of docetaxel. The median overall survival', '(OS) with the addition of docetaxel was significantly longer 57.6 months VS. 44.0 months', '(hazard ratio (HR) 0.61; 95% confidence interval {CI}, 0.47-0.80; P<0.001). These finding', 'were verified in the STAMPEDE trial where six cycles of docetaxel plus ADT also improved', 'clinical outcomes over ADT alone. The two docetaxel arms resulted in significant', 'improvement to os compared to the two ADT alone arms with hazard ratios of 0.78 (95% CI,', '0.66-093; p=0.006) and 0.82 (95% CI, 0.69-0.97; p=0.022) respectively.', 'Two studies have shown superior outcomes with the addition of abiraterone to ADT in', 'mHSPC, the LATITUDE³ and STAMPEDE4 (arms A and G) clinical trials. The LATITUDE', 'trial randomized 1199 patients and the STAMPEDE randomized 1917 patients to ADT versus', 'ADT plus abiraterone. The combination improved the median os in the LATITUDE trial (not', 'reached VS. 34.7 months; HR 0.62; 95% CI, 0.51-0.76; P<0.001) and improved 3 year', 'survival in the STAMPEDE trial at 83% VS 76% (HR 0.63; 95% CI 1.0.52-0.76; P<0.001).', 'These two approaches of combination therapy have not been directly compared so no high-', 'level evidence is available to make optimal treatment choices based on clinical outcomes.', 'Treatment decision is instead based on other clinical factors such as drug availability, fitness', 'for chemotherapy, toxicity or cost.', '5', 'There is likely a difference in these treatments regarding toxicities and cost. For instance,', 'docetaxel is known to cause alopecia, febrile neutropenia fatigue and neuropathy. Abiraterone', 'is known to cause fatigue, drug induced hepatitis and hypertension. There are differences in', 'the treatment duration as well with docetaxel given for 6 cycles (approximately 4 months)', 'whereas abiraterone is given until disease progression which may result in differences in', 'quality of life and does result in difference in financial expense. 6 The patient reported outcomes', 'in the LATITUDE study favored the combination group7. The reported quality of life was', 'initially worse with docetaxel than ADT alone at three months, but better than ADT alone at', '12 months in the CHAARTED study.8', 'Finally, there might be molecularly identified subgroups that will preferentially respond to a', 'hormonal based treatment (i.e. ADT + abiraterone) or a chemotherapy based treatment (i.e.', 'ADT + docetaxel). For instance, previous studies have demonstrated some subgroups of', 'patients in the castration-resistant setting that are more sensitive to docetaxel over', 'abiraterone.9-11', 'We hypothesize that treatment efficacy will be similar across the entire population studied in', 'this clinical trial between ADT + docetaxel versus ADT + abiraterone. However, we', 'Page 12 of 52']"
12,page_13,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'hypothesize that quality of life will be superior throughout the study for the abiraterone treated', 'patients. Doing this clinical trial directly comparing these two treatment options will also allow', 'for exploratory analysis of biomarkers of treatment response between hormonal versus', 'chemotherapy treatment in this population of patients which may identify additional factors', 'that may be important in the treatment selection between docetaxel and abiraterone for this', 'patient population.', '3', 'DRUG INFORMATION', '3.1', 'Androgen Deprivation Therapy', ""All subjects must receive ADT of Investigator's choice (LHRH agonist or antagonist, or"", 'orchiectomy) per FDA approved dosing regulations as standard therapy for the duration of the', 'clinical trial. Patients should maintain a castrate level testosterone concentration (i.e. total', 'testosterone VI 50 ng/dL) as validation of therapeutic efficacy for the chosen ADT therapy.', '3.2', 'Docetaxel (Taxotere)', 'Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells', 'that is essential for mitotic and interphase cellular functions.', 'Refer to Sanofi Package Insert for detail regarding clinical administration of TAXOTERE. The', 'following information is taken from the Package Insert', '3.2.1', 'Pharmacology', 'Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules', 'while simultaneously inhibiting their disassembly. This leads to the production of microtubule', 'bundles without normal function and to the stabilization of microtubules, which results in the', 'inhibition of mitosis in cells.', 'The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration', 'of 20 mg/m2 to 115 mg/m2 in phase 1 studies. The area under the curve (AUC) was dose', 'proportional following doses of 70 mg/m2 to 115 mg/m2 with infusion times of 1 to 2 hours.', ""Docetaxel's pharmacokinetic profile is consistent with a three-compartment pharmacokinetic"", 'model, with half-lives for the a., ß, and Y phases of 4 min, 36 min, and 11.1 hr, respectively.', 'Mean total body clearance was 21 L/h/m2.', 'Distribution: The initial rapid decline represents distribution to the peripheral compartments', 'and the late (terminal) phase is due, in part, to a relatively slow efflux of docetaxel from the', 'peripheral compartment. Mean steady state volume of distribution was 113 L. In vitro studies', 'showed that docetaxel is about 94% protein bound, mainly to x-1-acid glycoprotein, albumin,', 'and lipoproteins. In three cancer patients, the in vitro binding to plasma proteins was found to', 'be approximately 97%. Dexamethasone does not affect the protein binding of docetaxel.', 'Metabolism: In vitro drug interaction studies revealed that docetaxel is metabolized by the', 'CYP3A4 isoenzyme, and its metabolism may be modified by the concomitant administration', 'of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4.', 'Elimination: A study of 14C-docetaxel was conducted in three cancer patients. Docetaxel was', 'eliminated in both the urine and feces following oxidative metabolism of the tert-butyl ester', 'Page 13 of 52']"
13,page_14,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'group, but fecal excretion was the main elimination route. Within 7 days, urinary and fecal', 'excretion accounted for approximately 6% and 75% of the administered radioactivity,', 'respectively. About 80% of the radioactivity recovered in feces is excreted during the first 48', 'hours as 1 major and 3 minor metabolites with very small amounts (less than 8%) of unchanged', 'drug', '3.2.2', 'Pharmaceutical Properties and Formulation', 'Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by', 'semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew', 'plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine,N-tert-butyl', 'ester, 13-ester with 5ß-20-epoxy-1,2a,4,78,108,13a-hexahydroxytax-11-en-9-one 4-acetate 2-', 'benzoate, trihydrate. Docetaxel is a white to almost-white powder with an empirical formula', 'of', 'C43H53NO14 3H2O, and a molecular weight of 861.9. It is highly lipophilic and', 'practically insoluble in water', '3.2.3', 'Clinical Safety', 'The following data are based on the experience of 332 prostate cancer patients, who were', 'treated with TAXOTERE 75 mg/m² every 3 weeks in combination with prednisone 5 mg orally', 'twice daily:', '2', 'TAXOTERE 75 mg/m', 'Mitoxantrone 12 mg/m²', 'every 3 weeks +', 'every 3 weeks +', 'prednisone 5 mg twice', 'prednisone 5 mg twice', 'daily', 'daily', 'n=332', 'n=335', '%', '%', 'Adverse Reaction', 'Any', 'Grade 3/4', 'Any', 'Grade 3/4', 'Anemia', '67', '5', '58', '2', 'Neutropenia', '41', '32', '48', '22', 'Thrombocytopenia', '3', '1', '8', '1', 'Febrile neutropenia', '3', 'N/A', '2', 'N/A', 'Infection', '32', '6', '20', '4', 'Epistaxis', '6', '0', '2', '0', 'Allergic Reactions', '8', '1', '1', '0', 'Fluid Retention*', '24', '1', '5', '0', 'Weight Gain*', '8', '0', '3', '0', 'Peripheral Edema*', '18', '0', '2', '0', 'Neuropathy Sensory', '30', '2', '7', '0', 'Neuropathy Motor', '7', '2', '3', '1', 'Rash/Desquamation', '6', '0', '3', '1', 'Alopecia', '65', 'N/A', '13', 'N/A', 'Nail Changes', '30', '0', '8', '0', 'Page 14 of 52']"
14,page_15,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '2', 'TAXOTERE 75 mg/m', 'Mitoxantrone 12 mg/m', 'every 3 weeks +', 'every 3 weeks +', 'prednisone 5 mg twice', 'prednisone 5 mg twice', 'daily', 'daily', 'n=332', 'n=335', '%', '%', 'Adverse Reaction', 'Any', 'Grade 3/4', 'Any', 'Grade 3/4', 'Nausea', '41', '3', '36', '2', 'Diarrhea', '32', '2', '10', '1', 'Stomatitis/Pharyngitis', '20', '1', '8', '0', 'Taste Disturbance', '18', '0', '7', '0', 'Vomiting', '17', '2', '14', '2', 'Anorexia', '17', '1', '14', '0', 'Cough', '12', '0', '8', '0', 'Dyspnea', '15', '3', '9', '1', 'Cardiac left ventricular', '10', '0', '22', '1', 'function', 'Fatigue', '53', '5', '35', '5', 'Myalgia', '15', '0', '13', '1', 'Tearing', '10', '1', '2', '0', 'Arthralgia', '8', '1', '5', '1', '*Related to treatment', '3.3', 'Abiraterone Acetate (Abiraterone)', 'Abiraterone is an inhibitor of CYP17 (17a-hydroxylase/C17,20-lyase)', ""Abiraterone for this trial will be dispensed as part of the patient's standard of care therapy."", 'Depending on insurance and/or physician preference, Zytiga, Yonsa, or a generic abiraterone', 'acetate will be allowed. Dosing for each regimen should be consistent with FDA prescribing', 'information.', 'Refer to Package Insert for detail regarding clinical administration of Zytiga, Yonsa, or generic', 'abiraterone acetate. The following information is taken from these documents:', '3.3.1', 'Pharmacology', 'Abiraterone acetate (abiraterone) is converted in vivo to abiraterone, an androgen biosynthesis', 'inhibitor, that inhibits 17 a-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in', 'testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis.', 'CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone and progesterone', 'to their 17-hydroxy derivatives by 17a-hydroxylase activity and 2) the subsequent formation', 'of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17, 20 lyase', 'activity. DHEA and androstenedione are androgens and are precursors of testosterone.', 'Page 15 of 52']"
15,page_16,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Inhibition of CYP17 by abiraterone can also result in increased mineralocorticoid production', 'by the adrenals. Androgen sensitive prostatic carcinoma responds to treatment that decreases', 'androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or', 'orchiectomy, decrease androgen production in the testes but do not affect androgen production', 'by the adrenals or in the tumor. Abiraterone decreased serum testosterone and other androgens', 'in patients in the placebo-controlled clinical trial. It is not necessary to monitor the effect of', 'Abiraterone on serum testosterone levels. Changes in serum prostate specific antigen (PSA)', 'levels may be observed but have not been shown to correlate with clinical benefit in individual', 'patients.', '3.3.2', 'Physical and Chemical Properties', 'Abiraterone acetate is a white to off-white, non-hygroscopic, crystalline powder. Its molecular', 'formula is C26H33NO2 and it has a molecular weight of 391.55. Abiraterone acetate is', 'a', 'lipophilic compound with an octanol-water partition coefficient of 5.12 (Log P) and is', 'practically insoluble in water. The pKa of the aromatic nitrogen is 5.19.', '3.3.3', 'Pharmaceutical Properties and Formulation', 'Zytiga', 'Each Zytiga tablet contains either 250 mg or 500 mg of abiraterone acetate. Abiraterone acetate', 'is designated chemically as (38)-17-(3-pyridinyl) androsta5, 16-dien-3-yl acetate.', 'Zytiga tablets are available in 500 mg film-coated tablets, 250 mg film-coated tablets and', '250 mg uncoated tablets with the following inactive ingredients:', '500 mg film-coated tablets: colloidal silicon dioxide, croscarmellose sodium, hypromellose,', 'lactose monohydrate, magnesium stearate, silicified microcrystalline cellulose, and sodium', 'lauryl sulfate. The coating, OpadryR II Purple, contains iron oxide black, iron oxide red,', 'polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.', '250 mg film-coated tablets: colloidal silicon dioxide, croscarmellose sodium, lactose', 'monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl', 'sulfate. The coating, Opadry® II Beige, contains iron oxide red, iron oxide yellow,', 'polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.', '250 mg uncoated tablets: colloidal silicon dioxide, croscarmellose sodium, lactose', 'monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl', 'sulfate', 'Yonsa', 'Yonsa (abiraterone acetate) tablets, 125 mg, are white to off-white, oval-shaped tablets', 'debossed with ""125 FP"" on one side.', '3.3.4', 'Clinical Safety', 'Zytiga', 'In a placebo-controlled, multicenter phase 3 clinical trial of patients with metastatic castration-', 'resistant prostate cancer who were using a gonadotropin-releasing hormone (GnRH) agonist', 'or were previously treated with orchiectomy, abiraterone was administered at a dose of 1,000', 'mg daily in combination with prednisone 5 mg twice daily in the active treatment arm (N =', 'Page 16 of 52']"
16,page_17,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '791). Placebo plus prednisone 5 mg twice daily was given to control patients (N = 394). The', 'median duration of treatment with Abiraterone was 8 months. The most common adverse drug', 'reactions (5%) reported in clinical studies were joint swelling or discomfort, hypokalemia,', 'edema, muscle discomfort, hot flush, diarrhea, urinary tract infection, cough, hypertension,', 'arrhythmia, urinary frequency, nocturia, dyspepsia, and upper respiratory tract infection. The', 'most common adverse drug reactions that resulted in drug discontinuation were aspartate', 'aminotransferase increased, alanine aminotransferase increased, urosepsis and cardiac failure', '(each in <1% of patients taking abiraterone).', 'Adverse reactions and laboratory abnormalities related to mineralocorticoid effects were', 'reported more commonly in patients treated with abiraterone than in patients treated with', 'placebo: hypokalemia 28% versus 20%, hypertension 9% versus 7% and fluid retention', '(edema) 27% versus 18%, respectively. In patients treated with abiraterone, grades 3 to 4', 'hypokalemia occurred in 5% of patients and grades 3 to 4 hypertension was reported in 1% of', 'patients.', 'Cardiovascular Adverse Reactions:', 'The majority of arrhythmias were grade 1 or 2. Grade 3-4 arrhythmias occurred at similar rates', 'in the two arms. There was one death associated with arrhythmia and one patient with sudden', 'death in the abiraterone arm. No patients had sudden death or arrhythmia associated with death', 'in the placebo arm. Cardiac ischemia or myocardial infarction led to death in 2 patients in the', 'placebo arm and 1 death in the abiraterone arm. Cardiac failure resulting in death occurred in', '1 patient on both arms.', 'Hepatotoxicity:', 'Drug-associated hepatotoxicity with elevated ALT, AST, and total bilirubin has been reported', 'in patients treated with abiraterone. Across all clinical trials, liver function test elevations (ALT', 'or AST increases of > 5X ULN) were reported in 2.3% of patients who received abiraterone,', 'typically during the first 3 months after starting treatment. In the phase 3 trial, patients whose', 'baseline ALT or AST were elevated were more likely to experience liver function test', 'elevations than those beginning with normal values. When elevations of either ALT or AST >', '5X ULN, or elevations in bilirubin > 3X ULN were observed, abiraterone was withheld or', 'discontinued. In two instances marked increases in liver function tests occurred. These two', 'patients with normal baseline hepatic function, experienced ALT or AST elevations 15 to 40X', 'ULN and bilirubin elevations 2 to 6 X ULN. Upon discontinuation of abiraterone, both patients', 'had normalization of their liver function tests and one patient was re-treated with', 'ABIRATERONE without recurrence of the elevations. In clinical trials, the following patients', 'were excluded: patients with active hepatitis, patients with baseline ALT and/or AST > 2.5X', 'ULN in the absence of liver metastases, and patients with ALT and/or AST > 5X ULN in the', 'presence of liver metastases. Abnormal liver function tests developing in patients participating', 'in clinical trials were managed by treatment interruption, dose modification and/or', 'discontinuation [see Dosage and Administration (2.2) and Warnings and Precautions (5.3)].', 'Patients with elevations of ALT or AST > 20X ULN were not re-treated.', 'Page 17 of 52']"
17,page_18,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Yonsa', 'Hypertension, Hypokalemia and Fluid Retention Due to Mineralocorticoid Excess:', 'Yonsa may cause hypertension, hypokalemia, and fluid retention as a consequence of increased', 'mineralocorticoid levels resulting from CYP17 inhibition. Monitor patients for hypertension,', 'hypokalemia, and fluid retention at least once a month. Control hypertension and correct', 'hypokalemia before and during treatment with Yonsa.', 'In the two randomized clinical trials, grade 3 to 4 hypertension occurred in 2% of patients,', 'grade 3 to 4 hypokalemia in 4% of patients, and grade 3 to 4 edema in 1% of patients treated', 'with abiraterone acetate.', 'Co-administration of a corticosteroid suppresses adrenocorticotropic hormone (ACTH) drive,', 'resulting in a reduction in the incidence and severity of these adverse reactions. Closely', 'monitor patients whose underlying medical conditions might be compromised by increases in', 'blood pressure, hypokalemia or fluid retention, such as those with heart failure, recent', 'myocardial infarction, cardiovascular disease, or ventricular arrhythmia. The safety of Yonsa', 'in patients with left ventricular ejection fraction < 50% or New York Heart Association', '(NYHA) Class III or IV heart failure (in Study 1) or NYHA Class II to IV heart failure (in', 'Study 2) was not established because these patients were excluded from these randomized', 'clinical trials.', 'Adrenocortical Insufficiency:', 'Adrenal insufficiency occurred in the two randomized clinical studies in 0.5% of patients', 'taking abiraterone acetate and in 0.2% of patients taking placebo. Adrenocortical insufficiency', 'was reported in patients receiving abiraterone acetate in combination with corticosteroid,', 'following interruption of daily steroids and/or with concurrent infection or stress.', 'Monitor patients for symptoms and signs of adrenocortical insufficiency, particularly if', 'patients are withdrawn from corticosteroids, have corticosteroid dose reductions, or experience', 'unusual stress. Symptoms and signs of adrenocortical insufficiency may be masked by adverse', 'reactions associated with mineralocorticoid excess seen in patients treated with Yonsa. If', 'clinically indicated, perform appropriate tests to confirm the diagnosis of adrenocortical', 'insufficiency. Increased dosage of corticosteroids may be indicated before, during and after', 'stressful situations.', 'Hepatotoxicity:', 'In postmarketing experience, there have been abiraterone acetate-associated severe hepatic', 'toxicity, including fulminant hepatitis, acute liver failure and deaths.', 'In the two randomized clinical trials, grade 3 or 4 ALT or AST increases (at least 5X ULN)', 'were reported in 4% of patients who received abiraterone acetate, typically during the first 3', 'months after starting treatment. Patients whose baseline ALT or AST were elevated were more', 'likely to experience liver test elevation than those beginning with normal values. Treatment', 'discontinuation due to liver enzyme increases occurred in 1% of patients taking abiraterone', 'acetate. No deaths clearly related to abiraterone acetate were reported due to hepatotoxicity', 'events.', 'Measure serum transaminases (ALT and AST) and bilirubin levels prior to starting treatment', 'with Yonsa, every two weeks for the first three months of treatment and monthly thereafter. In', 'Page 18 of 52']"
18,page_19,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'patients with baseline moderate hepatic impairment receiving a reduced Yonsa dose of 125', 'mg, measure ALT, AST, and bilirubin prior to the start of treatment, every week for the first', 'month, every two weeks for the following two months of treatment and monthly thereafter.', 'Promptly measure serum total bilirubin, AST, and ALT if clinical symptoms or signs', ""suggestive of hepatotoxicity develop. Elevations of AST, ALT, or bilirubin from the patient's"", 'baseline should prompt more frequent monitoring. If at any time AST or ALT rise above five', 'times the ULN, or the bilirubin rises above three times the ULN, interrupt Yonsa treatment and', 'closely monitor liver function.', 'Re-treatment with Yonsa at a reduced dose level may take place only after return of liver', ""function tests to the patient's baseline or to AST and ALT less than or equal to 2.5X ULN and"", 'total bilirubin less than or equal to 1.5X ULN. Permanently discontinue treatment with', 'abiraterone acetate for patients who develop a concurrent elevation of ALT greater than 3 X', 'ULN and total bilirubin greater than 2 X ULN in the absence of biliary obstruction or other', 'causes responsible for the concurrent elevation. The safety of YONSA re-treatment of patients', 'who develop AST or ALT greater than or equal to 20X ULN and/or bilirubin greater than or', 'equal to 10X ULN is unknown.', '4', 'STUDY DESIGN', '4.1', 'Description', 'This is an open label, randomized prospective clinical trial. All patients will be treated with', 'ongoing standard of care ADT (surgical or medical castration, documented testosterone < 50', 'ng/dL while on study) plus either docetaxel intravenously (75mg/m2) once every 3 weeks for', '6 cycles or abiraterone orally until disease progression. Treatment will occur per standard of', 'care at the discretion of the treating physician. Radiographic disease assessment will be', 'performed per clinical indication. Study visits time points will be based on day 1 of treatment', 'and follow a consistent schedule, regardless of treatment delays. Patients will be followed until', 'disease progression or for 18 months, whichever occurs first.', '4.2', 'Number of Patients', 'A total of 89 subjects will be enrolled.', '4.3', 'Number of Study Centers', 'This will be a multi-institution trial conducted at the Huntsman Cancer Institute, at the', 'University of Utah. Up to an additional 7 other centers may be opened.', '4.4', 'Study Duration', 'This trial is expected complete enrollment within 24 months. Treatment is expected to continue', 'for an additional 18 months. The study will be completed after approximately 42 months.', 'Page 19 of 52']"
19,page_20,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '5', 'ELIGIBILITY CRITERIA', 'This eligibility checklist is used to determine patient eligibility and filed with the enrolling', ""investigator's signature in the patient research chart."", 'Patient No.', ""Patient's Initials: (L,F,M)"", '5.1', 'Inclusion Criteria', 'Yes/No (Response of ""no"" = patient ineligible)', '5.1.1', 'Male subject aged > 18 years.', '5.1.2', 'Histologically diagnosed adenocarcinoma of the prostate.', '5.1.3', 'Radiographically confirmed metastatic disease prior to patient enrollment.', 'Metastatic disease can be confirmed based on conventional imaging (CT, MRI,', 'nuclear medicine bone scan) or molecular imaging (fluciclovine-PET/CT, PSMA-', 'PET/CT, Choline-PET/CT etc).', '5.1.4', 'ECOG Performance Status 2.', '5.1.5', 'Adequate organ function as defined as:', 'Hematologic:', 'Absolute neutrophil count (ANC) > 1.5 k/L.', 'Platelets > 100 k/L.', 'Hepatic:', 'Serum total bilirubin 1.5 times upper limit of normal (ULN) OR direct', 'bilirubin ULN for subjects with total bilirubin > 1.5 X ULN.', 'AST or ALT 2.5 X ULN OR 4 X ULN for subjects with liver', 'metastases.', 'Renal:', 'Creatinine < 1.5 X ULN OR', 'Creatinine clearance > 50 mL/min for subject with creatinine levels > 1.5', 'ULN by Cockcroft-Gault fomula or standard institutional practice:', '(140-age)xweight(kg)', 'Males:', 'serum creatinine', 'mg', 'x72', 'dL', 'Females:', '(140-age) xweight[kg]', 'X 0.85', 'serum creatinine', 'mg', 'x72', 'dL', 'Page 20 of 52']"
20,page_21,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '5.1.6', 'Highly effective method of contraception for both male and female partners of', 'subjects throughout the study and for at least 3 months after last study treatment', 'administration if the risk of conception exists.', '5.1.7', 'Recovery to baseline or VI Grade 1 CTCAE v5.0 from toxicities related to any', 'prior treatments, unless AE(s) are clinically nonsignificant and/or stable on', 'supportive therapy as defined by the treating physician.', '5.1.8', 'Able to provide informed consent and willing to sign an approved consent', 'form that conforms to federal and institutional guidelines.', '5.2', 'Exclusion Criteria', 'Yes/No (Response of ""yes"" = patient ineligible)', '5.2.1', 'No prior abiraterone or docetaxel therapy for metastatic hormone sensitive', 'prostate cancer. Prior therapy with ADT or first generation anti-androgen receptor', 'therapy (example: bicalutamide) is allowed.', '5.2.2', 'Completed any hormone therapy for localized prostate cancer and have', 'recovery of testosterone (i.e. testosterone level is >50ng/dL).', '5.2.3', 'Patients have a histologic diagnosis of small cell prostate cancer or pure', 'squamous cell prostate cancer.', '5.2.4', 'Known brain metastases or cranial epidural disease unless adequately treated', 'with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4', 'weeks before first dose of study treatment. Eligible subjects must be neurologically', 'asymptomatic and without corticosteroid treatment at the time of first dose of study', 'treatment.', '5.2.5', 'The subject has uncontrolled, significant intercurrent or recent illness', 'including, but not limited to, the following conditions:', 'Cardiovascular disorders:', 'Congestive heart failure New York Heart Association Class 3 or 4, unstable', 'angina pectoris, serious cardiac arrhythmias within 3 months of study', 'enrollment.', 'Uncontrolled hypertension defined as sustained blood pressure (BP) > 170', 'mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive', 'treatment.', 'Stroke (including transient ischemic attack [TIA]), myocardial infarction', '(MI), or other ischemic event, or arterial thromboembolic event within 3', 'months before first dose.', 'Other clinically significant disorders that would preclude safe study participation.', 'As defined by the treating physician', 'Page 21 of 52']"
21,page_22,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '5.2.6', 'Known history of testing positive for HIV and CD4 count is below 200 or', 'known acquired immunodeficiency syndrome diagnosis.', '5.2.7', 'Known history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection', 'at screening (positive HBV surface antigen or detectable HCV RNA if anti-HCV', 'antibody screening test positive) and a detectable viral count at screening.', '5.2.8', 'Use of live virus vaccine within 4 weeks of the first dose of treatment or', 'planned use while on trial for the duration of potential docetaxel treatment. Live', 'vaccine use is acceptable after chemotherapy or for patients randomized to the', 'abiraterone arm. There are no restrictions on inactive viruses.', '5.2.9', 'Known prior severe hypersensitivity to investigational product or any', 'component in its formulations (NCI CTCAE v5.0 Grade > 3).', 'I certify that this patient meets all inclusion and exclusion criteria for enrollment onto this', 'study.', 'Investigator Signature', 'Date', 'Time', 'Page 22 of 52']"
22,page_23,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '5.3', 'Recruitment Strategies', 'Potential patients will be identified by Investigators in the setting of their outpatient clinics.', '6', 'RANDOMIZATION', 'Patients will be randomized in a 1:1 manner. Patients will be stratified based on Gleason score', '(<8 versus > 8) and the presence of visceral metastasis (yes versus no). Visceral metastasis is', 'defined as liver, lung, or central nervous system (CNS) involvement.', '7', 'TREATMENT PLAN', '7.1', 'Administration Schedule', 'Treatment will occur per standard of care at the discretion of the treating physician. All study', 'drugs will be provided by commercial supply. Study visits will be anchored to day 1 of', 'treatment, without regard for changes to treatment schedule.', 'Patients who are unable to initiate docetaxel or abiraterone therapy within 42 days of', 'randomization will be replaced.', '7.2', 'Docetaxel', '7.2.1', 'How Supplied, Stored, Packaged and Labeled', 'Docetaxel Injection Concentrate is a clear yellow to brownish-yellow viscous solution.', 'Docetaxel is sterile, non-pyrogenic, and is available in single-dose vials containing 20 mg (0.5', 'mL) or 80 mg (2 mL) docetaxel (anhydrous). Each mL contains 40 mg docetaxel (anhydrous)', 'and 1040 mg polysorbate 80.', 'TAXOTERE Injection Concentrate requires dilution with Diluent prior to addition to the', 'infusion bag. A sterile, non-pyrogenic, single-dose diluent is supplied for that purpose. The', 'diluent for TAXOTERE contains 13% ethanol in water for injection, and is supplied in vials.', '7.2.2', 'Preparation and Administration', 'The docetaxel should be dosed and administered per institutional standards in accordance with', 'FDA approved usage. Cycles should be repeated approximately every 3 weeks for 6 cycles.', 'Treatment delays and potential dose modifications will occur per standard of care at the', 'discretion of the treating physician, to reflect the clinical setting as much as possible.', 'The recommended pre-medication regimen is oral dexamethasone 8 mg, 12 hours, 3 hours and', '1 hour before the docetaxel infusion. However, other schedules or use of a different', 'corticosteroid is also acceptable consistent with local practice. Anti-emetic regimens are', 'recommended as per local clinical practice.', 'Preparation procedures are detailed in the package insert.', 'Page 23 of 52']"
23,page_24,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '7.3', 'Zytiga (Abiraterone)', '7.3.1', 'How Supplied, Stored, Packaged and Labeled', 'Zytiga', '250 mg tablets are white to off-white, oval tablets debossed with AA250 on one side. Zytiga', '250 mg tablets are available in high-density polyethylene bottles of 120 tablets.', 'Store at 20° C to 25° C (68° F to 77° F); excursions permitted to 15° C to 30° C (59° F to 86°F).', 'Based on its mechanism of action, Zytiga may harm a developing fetus. Therefore, women', 'who are pregnant or women who may be pregnant should not handle Zytiga without protection', '(e.g., gloves).', 'Yonsa', 'Tablets, 125 mg, are white to off-white, oval-shaped tablets debossed with ""125 FP"" on one', 'side.', 'Store at 20° C to 25° C (68° F to 77° F); excursions permitted to 15° C to 30° C (59° F to 86°F).', 'Women who are pregnant or women who may be pregnant should not handle Yonsa without', 'protection, e.g., gloves.', '7.3.2', 'Preparation and Administration', 'Zytiga', 'The Zytiga should be dosed and administered per institutional standards and in accordance', 'with FDA approved use. The package insert recommends 1,000 mg administered orally once', 'daily in combination with prednisone 5 mg administered orally twice daily. No food should be', 'consumed for at least two hours before the dose of Zytiga is taken and for at least one hour', 'after the dose of Zytiga is taken.', 'Yonsa', 'The Yonsa should be dosed and administered per institutional standards and in accordance', 'with FDA approved use. The recommended dose of YONSA is 500 mg (four 125 mg tablets)', 'administered orally once daily in combination with methylprednisolone 4 mg administered', 'orally twice daily with or without food.', '7.3.3', 'Accountability and Compliance', 'Abiraterone tablets will be supplied per standard practice of the treating physician and', 'pharmacy.', '7.4', 'Concomitant Medications and Therapies', '7.4.1', 'Prohibited Therapy', '7.4.1.1 Docetaxel', 'Docetaxel is a CYP3A4 substrate. In vitro studies have shown that the metabolism of', 'docetaxel may be modified by the concomitant administration of compounds that', 'induce, inhibit, or are metabolized by cytochrome P450 3A4. In vivo studies showed', 'Page 24 of 52']"
24,page_25,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'that the exposure of docetaxel increased 2.2-fold when it was coadministered with', 'ketoconazole, a potent inhibitor of CYP3A4. Protease inhibitors, particularly ritonavir,', 'may increase the exposure of docetaxel. Concomitant use of docetaxel and drugs that', 'inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. In patients', 'receiving treatment with docetaxel, close monitoring for toxicity and a docetaxel dose', 'reduction could be considered if systemic administration of a potent CYP3A4 inhibitor', 'cannot be avoided', '7.4.1.2 Abiraterone', 'Abiraterone is an inhibitor of the hepatic drug-metabolizing enzyme CYP2D6. In', 'a', 'CYP2D6 drug-drug interaction trial, the Cmax and AUC of dextromethorphan', '(CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively, when', 'dextromethorphan was given with abiraterone acetate 1,000 mg daily and prednisone 5', 'mg twice daily. Avoid coadministration of abiraterone acetate with substrates of', 'CYP2D6 with a narrow therapeutic index (e.g., thioridazine). If alternative treatments', 'cannot be used, exercise caution and consider a dose reduction of the concomitant', 'CYP2D6 substrate drug.', 'Abiraterone is also a substrate of CYP3A4. The effects of strong CYP3A4 inhibitors', '(e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir,', 'telithromycin, ritonavir, indinavir, nelfinavir, voriconazole) or inducers (e.g., phenytoin,', 'carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital) on the pharmacokinetics', 'of abiraterone have not been evaluated, in vivo. Avoid or use with caution, strong', 'inhibitors and inducers of CYP3A4 during abiraterone treatment.', '7.5', 'Duration of Therapy', 'Arm A: Patients will receive 6 cycles of docetaxel, given approximately every 3 weeks, in', ""addition to physician's choice ADT."", ""Arm B: Patients will receive abiraterone continuously, in addition to physician's choice ADT,"", 'until disease progression.', '7.5.1', 'Criteria for discontinuation of treatment (""off treatment"")', 'The following will result in treatment discontinuation:', 'Subject withdraws consent from the study treatment and/or study procedures.', 'Diagnosis of progression, per the discretion of the treating physician. The protocol', 'suggests defining progression based on radiographic or clinical progression and not', 'PSA only progression.', ""AEs or intercurrent illness that in the opinion of the investigator warrants the subject's"", 'withdrawal from study treatment.', 'Significant noncompliance with the protocol schedule or treatment administration in', 'the opinion of the investigator.', '7.5.2', 'Criteria for discontinuation of study (""off study"")', 'Subjects will be taken off study for the following:', 'Page 25 of 52']"
25,page_26,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Completed study follow-up period', 'Participant requests to be withdrawn from study', 'Death', 'Subject is lost to follow-up', '8', 'TOXICITIES AND DOSEAGE MODIFICATION', 'This study will utilize the CTCAE (NCI Common Terminology Criteria for Adverse Events)', 'Version 5.0 for adverse event and serious adverse event reporting.', '8.1', 'Dose Modifications and Guidelines for Adverse Event Management', '8.1.1', 'Dose Modifications', 'Dose adjustments for ADT, docetaxel, and abiraterone will be left to the discretion of treating', 'investigator. Toxicities should be monitored and managed per institutional practice.', '8.2', 'Supportive Care', 'All supportive measures consistent with optimal patient care may be given throughout the', 'study.', '8.3', 'Contraception', 'For this trial, male subjects will be considered to be of non-reproductive potential if they have', 'azoospermia (whether due to having had a vasectomy or due to an underlying medical', 'condition).', 'Male subjects of reproductive potential must agree to avoid impregnating a partner while', 'receiving study drug and for 3 months after the last dose of study drug by complying with one', 'of the following:', '(1) practice abstinence from heterosexual activity;', 'OR', '(2) use (or have their partner use) acceptable contraception during heterosexual activity.', 'Acceptable methods of contraception are+:', 'Single method (one of the following is acceptable):', 'intrauterine device (IUD)', 'contraceptive rod implanted into the skin', 'Combination method (requires use of two of the following):', 'diaphragm with spermicide (cannot be used in conjunction with cervical', 'cap/spermicide)', 'cervical cap with spermicide (nulliparous women only)', 'contraceptive sponge (nulliparous women only)', 'male condom or female condom (cannot be used together)', 'Page 26 of 52']"
26,page_27,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'hormonal contraceptive: oral contraceptive pill (estrogen/progestin pill or', 'progestin-only pill), contraceptive skin patch, vaginal contraceptive ring, or', 'subcutaneous contraceptive injection', 'Subjects should be informed that taking the study medication may involve unknown risks', 'to the fetus (unborn baby) if pregnancy were to occur during the study. In order to', 'participate in the study subjects of childbearing potential must adhere to the contraception', 'requirement (described above) from the day of study medication initiation (or 14 days prior', 'to the initiation of study medication for oral contraception) throughout the study period up', 'to 3 months for males after the last dose of trial therapy. If there is any question that a', 'subject of childbearing potential will not reliably comply with the requirements for', 'contraception, that subject should not be entered into the study.', 'Page 27 of 52']"
27,page_28,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '9', 'STUDY CALENDAR', 'Months (+/-4 days)', 'Progression11', 'Protocol Procedures', 'Screening¹', 'M0', 'M3', 'M6', 'M9', 'M12', 'M18', '(Day 1)', 'Informed Consent', 'X', 'Inclusion/Exclusion Criteria', 'X', 'Vital Signs', 'X2', 'Physical Exam with ECOG', 'X', 'Complete Blood Count (CBC) with Platelet Count, Differential', 'X', 'Comprehensive Metabolic Panel (CMP)', 'X', 'Urinalysis', 'X', 'Testosterone', 'X', 'PSA', 'X8', 'X', 'X', 'X', 'X', 'CT - Chest/Abdomen/Pelvis10', 'X', 'X³', 'X', 'Whole Body Bone Scan', 'X', 'X', 'Archival Tissue Submission (if available)', 'X4', 'Fresh Tissue Collection', 'Correlative Blood Collection6', 'X8', 'X', 'X', 'ADT + Docetaxel or ADT + Abiraterone', 'Questionnaires - FACT P, FACT/GOG-NTX, PROMIS Fatigue', 'X8', 'X', 'X', 'X', 'Adverse Event Collection13', 'X', 'X', 'Medical History', 'X', 'Exploratory Questionnaires¹2', 'X', 'X', 'Extent of Metastases Form (Appendix 1)', 'X', 'Note: All visits will be based on treatment start date and will be performed independent of treatment cycles and/or delays. 1', 'month will be defined as 28 days.', 'Page 28 of 52']"
28,page_29,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '1) Screening procedures should be performed within 28 days of Day 1 (Treatment initiation). There is no window designated for the screening diagnostic', 'CT and/or bone scan prior to study enrollment.', '2)', 'Vitals include height, weight, blood pressure, pulse, and temperature.', '3) To be repeated per clinical indication.', '4) To be performed prior M3 visit.', '5)', 'If the patient has consented to optional tissue collection, tissue may be collected from any SOC biopsy performed while on trial or at the end of treatment', '(month 18 or progression visit, whichever comes first).', '6)', 'If the patient consents to optional blood collection, blood will be collected at month 0 (prior to treatment), month 3, month 6 and the end of treatment', '(month 18 or progression visit, whichever comes first).', '7) Treatment length will depend on randomization assignment. Arm A will receive ADT + Docetaxel IV approximately Q3weeks x 6 cycles. Arm B will', 'receive ADT + Abiraterone PO (per drug-specific dosing guidelines), unless there is disease progression.', '8) To be performed prior to treatment initiation on Day 1. If treatment initiation is delayed by >4 days after completion of baseline questionnaires, these', 'should be repeated.', '9) Testosterone should be monitored monthly, or per institutional standard of care, to confirm castrate level testosterone concentration (i.e. total', 'testosterone V 50 ng/dL).', '10) Imaging techniques and sequences should be performed per institutional standard of care. Axumin PET CT Skull Base to Mid-Thigh', 'will', 'be', 'allowed', 'at screening.', '11) Procedures required at the time of progression will be performed within +/- 30 days of diagnosis of progression. Diagnosis of progression is per the', 'discretion of the treating physician. The protocol suggests defining progression based on radiographic or clinical progression and not PSA only', 'progression.', '12) The Overall Treatment Utility (OTU) form, Was It Worth It (WIWI) questionnaire, and End of Study Evaluation Form will be administered to patients', 'for', 'exploratory', ""purposes. The OTU for should be completed by the treating physician at the patient's 3 month visit and the WIWI questionnaire and"", 'End of Study Evaluation Form administered to the patient at the end of treatment (month 18 or progression visit, whichever comes first).', '13) Due to extensive characterization of study treatment regimens through previous clinical trials and in the standard clinical context, adverse event', 'collection will be limited in scope and occur in accordance with recording and reporting guidelines set forth in Section 16.2.', 'Page 29 of 52']"
29,page_30,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '10', 'STUDY PROCEDURES', '10.1', 'Screening Evaluations', 'Informed Consent', 'Review of Inclusion/Exclusion Criteria', 'Review of Medical History', 'Vital Signs, including height, weight, blood pressure, pulse, and temperature', 'Physical Exam', 'ECOG Performance Status', 'Laboratory assessments:', 'CBC with differential', 'CMP, including Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine', 'Aminotransferase, Total Bilirubin, Calcium, Carbon Dioxide, Creatinine, Chloride,', 'Glucose, Potassium, Protein, Sodium, and Urea Nitrogen', 'Urinalysis', 'Prostate-specific antigen (PSA)', 'Testosterone', 'CT scans of chest/abdomen/pelvis', 'Whole body bone scan', '10.2', 'On Treatment Evaluations', 'After the patient is determined to be eligible and is registered on the trial he will be randomized', '1:1 using block randomization to ADT + abiraterone or ADT + docetaxel. Treatment will occur', 'per standard of care at the discretion of the treating physician. Radiographic disease assessment', 'will be performed per clinical indication and at the time of progression. Study visits time points', 'will be based on day 1 of treatment and follow a consistent schedule, regardless of treatment', 'delays. Patients will be followed until disease progression or for 18 months, whichever occurs', 'first.', '10.2.1', 'Day 1 (Month 0) and at Months 3, 6, 9, 12, 18', 'Archival Tissue Submission. This should be performed anytime between registration and', 'prior M3 visit.', 'Laboratory assessments:', 'Prostate-specific antigen (PSA)', 'Correlative Blood Collection - Only months 0 (prior to treatment), 3, 6, and 18 or at', 'progression, if prior. (optional)', 'Questionnaires:', 'FACT-P-TOI', 'FACT/GOG-NTX', 'Page 30 of 52']"
30,page_31,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'To avoid duplicate FACT answers, subjects only need to complete the', '11 additional questions that specifically address sensory and motor', 'neuropathy symptoms within the FACT/GOG-NTX. [Appendix C', 'PROMIS Fatigue', 'Tissue may be procured from a standard of care biopsy at any point while on study.', 'Month 3 Only - Overall Treatment Utility (OTU) form to be completed by treating', 'physician', 'Month 18 Only, if patient has not progressed prior - Was It Worth It (WIWI) questionnaire', 'and End of Study Evaluation Form to be completed by patient', '10.2.2', 'At the time of Progression, if prior to M18 visit', 'Correlative Blood Collection', 'Tissue may be procured from a standard of care biopsy at the time of progression.', 'CT scans of chest/abdomen/pelvis', 'Whole body bone scan', 'Was It Worth It (WIWI) questionnaire and End of Study Evaluation Form to be completed', 'by patient', '11', 'CRITERIA FOR EVALUATION AND ENDPOINT', '11.1', 'Safety', 'Routine safety and tolerability may be evaluated from the results of reported signs and', 'symptoms, scheduled physical examinations, vital sign measurements, and clinical laboratory', 'test results. More frequent safety evaluations may be performed if clinically indicated or at the', 'discretion of the investigator.', 'Physical Examination', 'Complete and symptom-directed physical examinations will be performed by a licensed', ""physician (or physician's assistant or nurse practitioner)."", 'Vital Signs', 'Vital signs (blood pressure, respiratory rate, pulse rate and temperature) will be obtained per', 'institutional practice. Height and weight will be taken at screening.', 'Safety Laboratory Determinations', 'Laboratory evaluations will be performed as noted in the flow chart.', '11.2', 'Efficacy', 'Prostate-specific antigen will be evaluated throughout treatment to determine optimal PSA', 'response in both arms as well as PSA-PFS time points between treatment arms. This study will', 'use the PCGW3 criteria to define PSA-PFS18 PCWG3 defines PSA progression as the', 'date', 'that an increase of 25% or more and absolute increase of 2 ng/mL or more from the nadir are', 'documented. For patients who had an initial PSA decline during treatment, this must be', 'confirmed by a second value 3 or more weeks later.', 'Page 31 of 52']"
31,page_32,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '12', 'STATISTICAL CONSIDERATIONS', '12.1', 'Primary Objective and Endpoint', 'To assess the impact of abiraterone and docetaxel on total quality of life between screening', 'and month 12 of the study. The Functional Assessment of Cancer Therapy -Prostate (FACT-', 'P) questionnaire will be administered at baseline and month 12. The FACT-P is a 39 item', 'questionnaire that measures health-related quality of life in men with prostate cancer.14 The', 'FACT-P Trial Outcome Index (TOI) is the sum of the Physical Well-Being (PWB), Functional', 'Well-Being (FWB), and Prostate Cancer Subscales (PCS). TOI Scores will be quantified and', 'compared between treatment arms.', '12.2', 'Statistical Hypothesis', 'We hypothesize that abiraterone will have improved quality of life measurements at month 12', 'compared to docetaxel based on comparison of data from CHAARTED8 and LATITUDE.7', '12.3', 'Secondary Objective and Endpoint', '-', 'FACT/GOG-NTX: The FACT/GOG-NTX is a 38 item questionnaire that assesses patient', 'self-report of neuropathy. 15 It is a combination of the 27-item FACT-G (which is also part', 'of the FACT-P) plus 11 additional questions that specifically address sensory and motor', 'neuropathy symptoms.', '-', 'PROMIS Fatigue: The PROMIS Fatigue scale is a 7-item self-report measure designed to', 'assess severity, frequency, and daily pattern of fatigue (www.nihpromis.com). It has been', 'validated in cancer populations. 16', '12.4', 'Sample Size Determination', 'We hypothesize that patients on the ADT + Abiraterone arm will experience a superior overall', 'QOL at month 12 after enrollment in the study. Cella (2008) reports that a minimally important', 'difference in FACT-P TOI is a (standardized) effect size of 0.42 - 0.57. Power was calculated', 'via simulations in R using a Gaussian approximation for FACT-TOI analyzed using a mixed', 'effects model with fixed effects for treatment arm and categorical assessment time and a', 'random intercept for each subject. We assumed correlation = 0.5 between baseline and follow', 'up FACT-P TOI. We computed power for a comparison of the standardized change in FACT-', 'P TOI from baseline to 12 months. With the above assumption 40 subjects with complete data', 'per group will provide 80% power to detect a standardized effect size difference of 0.56', 'between the randomized groups at two sided alpha = 0.05.', 'The sample size of 80 patients is calculated based on the number of patients with complete', 'data. If there are patients with incomplete follow up data, they will contribute to the intent to', 'treat population. We assume 10% of patients will have incomplete data. To account for this', 'increased uncertainty the sample size will be increased to 89.', '12.5', 'Statistical Methods', 'Quality Of Life Enppoints', 'The primary and secondary outcome variables are patient reported quality of life, including the', 'FACT-P TOI (the primary outcome variable), and FACT/GOG NTX and PROMIS Fatigue', 'Page 32 of 52']"
32,page_33,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '(secondary outcome variables) assessed at baseline, 3, 6, 9, 12, and 18 months. Each of these', 'outcomes will be analyzed using Gaussian repeated measures mixed-effects models. The', 'models will contain random intercepts, fixed effects for each follow up assessment time and', 'interaction terms for treatment arm and follow up assessment time. The primary analysis will', 'be use a modified intent-to-treat strategy. Multiple imputation methods will be used to impute', 'missing questionnaire data for each subject who completes a baseline questionnaire. The mixed', 'effects models will also be used to report the mean and standard error of the change from', 'baseline at each of the follow up time points at which the questionnaires are administered (3,', '6, 9, 12, 18 months). The area under the curve from 0 to 12 months will also be reported. Joint', 'modeling of longitudinal FACT-P TOI and survival may be used as an additional sensitivity', 'analysis to explore changes in QOL over time.', 'The primary hypothesis is that patients on the ADT + Abiraterone arm will experience a', 'superior overall QOL at month 12 after enrollment in the study. This single primary hypothesis', 'will be tested at the two sided 0.05 significance level (unadjusted) using the interaction term', 'between treatment arm and the 12 month follow up time from the mixed effects model for', 'FACT-P TOI described above. Tests of interaction between treatment arm and the 12 month', 'follow up time will also be performed for the models for FACT/GOG NTX and PROMIS', 'Fatigue at the two sided 0.05 significance level (unadjusted).', 'PSA Response and PSA Progression Free Survival', 'PSA will be measured every three months while on study. The proportion of subjects', 'experiencing a 50% and 90% reduction in PSA as defined by the Prostate Cancer Working', 'Group 3 will be reported for each study arm, along with exact 95% confidence intervals', '(Clopper-Pearson). The proportion of PSA responders as defined by each of the above criteria', ""will be compared between treatment arms using Fisher's Exact test at the two sided 0.05"", 'significance level (unadjusted).', 'PSA Progression free survival (PSA-PSF) will be plotted using Kaplan-Meier methods. PSA-', 'PFS will be compared between the treatment arms using a log-rank test at the two sided 0.05', 'significance level (unadjusted). Subjects that have not experience PSA progression at the end', 'of study will be censored for PSA progression at the time of last on-study PSA evaluation.', '13', 'REGISTRATION GUIDELINES', 'Study related screening procedures can only begin once the patient has signed a consent', 'form.', 'Patients must meet all of the eligibility requirements listed above prior to registration.', 'Patients must be registered before receiving any study treatment and must begin treatment', 'within 42 days after randomization.', 'To register eligible patients on study, complete a Clinical Trials Office Patient Registration Form', 'and submit to CTORegistrations@hci.utah.edu', '14', 'DATA SUBMISSION SCHEDULE', 'The Case Report Forms (CRFs) are a set of (electronic or paper) forms for each patient that', ""provides a record of the data generated according to the protocol. CRF's should be created prior"", 'Page 33 of 52']"
33,page_34,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'to the study being initiated and updated (if applicable) when amendments to the protocol are IRB', 'approved. These forms will be completed on an on-going basis during the study. The medical', 'records will be source of verification of the data. During the study, the CRFs will be monitored for', 'completeness, accuracy, legibility and attention to detail by a member of the Research Compliance', 'Office. The CRFs will be completed by the Investigator or a member of the study team as listed', 'on the Delegation of Duties Log. The data will be reviewed no less than annually by the Data and', 'Safety Monitoring Committee. The Investigator will allow the Data and Safety Monitoring', 'Committee or Research Compliance Office personnel access to the patient source documents,', 'clinical supplies dispensing and storage area, and study documentation for the above-mentioned', 'purpose. The Investigator further agrees to assist the site visitors in their activities.', 'Data capture should be restricted to endpoints and relevant patient information required for', 'planned manuscripts.', '15', 'SPECIAL INSTRUCTIONS', '15.1', 'Correlative Studies', '15.1.1', 'Correlative Tissue Samples', 'Available archival tissue will be sent to Foundation Medicine to test for biomarkers of disease', 'response and prediction of treatment effect, such as, but not limited to: next generation', 'sequencing of tumor DNA and whole transcriptome analysis. NGS may be performed to assess', 'for changes to tumor suppressors and the androgen receptor, as these have been demonstrated', 'to be mechanisms of resistance to therapy.', 'If the patient consents to the optional tissue, up to 4 research cores will be collected any time', 'the patient has a standard of care biopsy while on study. Testing may include, but is not limited', 'to:', 'Multiomics platforms', 'Immunohistochemistry', 'Flow cytometry', 'Specimen collection and processing instructions can be found in the lab manual.', '15.1.2', 'Correlative Blood Samples', 'If the patient consents to provide optional blood samples, up to 54mL of peripheral blood will', 'be collected at the timepoints listed in the study calendar. Testing may include, but is not', 'limited to:', 'Circulating tumor cells (CTC) detection, enumeration, and characterization', 'Cytokine/chemokine/interferor assays', 'Genomic analysis', 'Proteomic analyses', 'Flow Cytometry', 'Detection of somatic and germline DNA alterations by targeted sequencing of cell-', 'free DNA.', 'Page 34 of 52']"
34,page_35,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Detection of androgen receptor splice variant 7 (ARV7) by droplet digital PCR', '(ddPCR).', 'Specimen collection and processing instructions can be found in the lab manual.', '16', 'ETHICAL AND REGULATORY CONSIDERATIONS', '16.1', 'Informed consent', 'Informed consent will be obtained from all research participants prior to performing any study', 'procedures using the most recent IRB-approved version.', '16.1.1', 'Participation of Children', 'Patients must be at least 18 years of age to participate.', '16.2', 'Institutional Review', 'Before study initiation, the investigator must have written and dated approval/favorable', 'opinion from the IRB/IEC for the protocol, consent form, subject recruitment materials (eg,', 'advertisements) and any other applicable patient-facing documents. The investigator should', 'also provide the IRB/IEC with a copy of the Investigator Brochure or product labeling', 'information.', 'The investigator or designee should provide the IRB/IEC with reports, updates and other', 'information (eg, expedited safety reports, amendments, and administrative letters) according', 'to regulatory requirements or institution procedures. Data and Safety Monitoring Plan', 'A Data and Safety Monitoring Committee (DSMC) is established at Huntsman Cancer Institute', '(HCI) to ensure the well-being of patients enrolled on Investigator Initiated Trials that do not', 'have an outside monitoring review. The roles and responsibilities of the DSMC are set forth in', 'the NCI-approved Data and Safety Monitoring (DSM) plan. The activities of the committee', 'include reviewing adverse events (including SAEs), deviations, important medical events,', 'significant revisions or amendments to the protocol, and approving cohort/dose escalations. If', 'the DSMC and/or the PI have concerns about unexpected safety issues, the study will be', 'stopped and will not be resumed until the issues are resolved. The DSMC also reviews and', 'approves audit reports generated by the Research Compliance Office.', 'This is a multicenter treatment study classified as high risk per the NCI-approved DSM plan.', 'Each high-risk study will be assigned a physician member of the DSMC as medical monitor,', 'or in rare cases, an external medical monitor. The medical monitor will be notified of all serious', 'adverse events (SAEs). Specific notifications will also be issued when a dose-limiting toxicity', 'is encountered and when the MTD dose is defined. Approval of the medical monitor is required', 'for all dose escalations. All serious adverse events (SAEs) occurring in patients treated at HCI', 'or its affiliates will also be reviewed by the full DSMC monthly. The full committee will also', 'review all toxicities for patients on treatment and within 30 days of their last treatment on a', 'quarterly basis.', 'Page 35 of 52']"
35,page_36,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Each high-risk study will also be assigned a dedicated research compliance officer who will', 'monitor the trial. High-risk studies will be monitored by RCO personnel after the first patient', 'is enrolled and every three months thereafter during active enrollment. The RCO monitor will', 'review the study status and summarize enrollment, toxicities, SAEs, dose escalation, statistical', 'endpoints (e.g., stopping rules), deviations, etc. for the full DSMC membership at the regularly', 'scheduled meetings. Amendments which increase risk, change dosing, or impact study', 'objectives will be reviewed by the DSMC and approved by the PRMC and IRB. High-risk', 'trials will be formally reviewed by the DSMC after the first patient is enrolled and then', 'quarterly thereafter.', 'An initial audit of high-risk studies will be conducted by the RCO approximately one year', 'after enrollment begins and annually thereafter. Audits of high-risk studies may be conducted', 'more frequently as requested by the DSMC, IRB, PRMC, RCO management, or the PI.', 'Adverse Events and Serious Adverse Events', 'This study will utilize the CTCAE (NCI Common Terminology Criteria for Adverse Events)', 'Version 5.0 for AE and SAE reporting.', '16.2.1', 'Adverse Events (AEs)', 'An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical', 'condition occurring after starting the study drug even if the event is not considered to be related', 'to study drug. For the purposes of this study, the terms toxicity and adverse event are used', 'interchangeably. Medical conditions/diseases present before starting study drug are only', 'considered adverse events if they worsen after starting study drug. Abnormal laboratory values', 'or test results constitute adverse events only if they are considered clinically significant by the', 'treating investigator, or require therapy to treat.', 'Collection of adverse events will begin after the first dose of study drug and end at the Month', '18', 'visit or 30 days after the last dose of study drug if the patient is removed for progression', 'prior to this time point.', 'The safety profile for the drugs involved in this study have been characterized extensively in', 'previous clinical trials and standard clinical contexts. As such, safety data collection for this', 'study will be limited to > Grade 3 adverse events as defined by CTCAE v5.0.', 'Information about adverse events, whether volunteered by the subject, discovered by', 'investigator questioning, or detected through physical examination, laboratory test or other', ""means, will be abstracted from standard investigator clinic notes and recorded in the patient's"", 'study chart, at the interval noted in the study calendar.', 'Adverse events meeting the aforementioned recording criteria should be further evaluated,', 'either through abstraction of standard investigator clinic notes or through direct', 'correspondence with the treating investigator to determine:', '1. The severity grade based on CTCAE v5.0 (grade 1-5)', '2. Its relationship to the study drugs (definite, probable, possible, unlikely, not related)', '3. Its duration (start and end dates or if continuing at final exam)', 'Page 36 of 52']"
36,page_37,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '4. Action taken (no action taken; study drug dosage adjusted/temporarily interrupted;', 'study drug permanently discontinued due to this adverse event; concomitant', 'medication taken; non-drug therapy given; hospitalization/prolonged hospitalization)', '5. Whether it constitutes an SAE', 'All adverse events will be treated as medically appropriate.', 'All CTCAE v5.0 Grade 3 and above adverse events should be followed until its resolution or', 'the patient discontinues study, and assessment should be made at the interval noted in the study', 'calendar (or more frequently, if necessary) of any changes in severity, suspected relationship', 'to the study intervention, interventions employed to treat it, and outcome.', '16.2.2 Serious Adverse Event (SAE)', 'Information about all serious adverse events, as defined below, will be collected and recorded.', 'A serious adverse event is an undesirable sign, symptom or medical condition which:', 'Is fatal or life-threatening', 'Results in persistent or significant disability/incapacity', 'Is medically significant, i.e., defined as an event that jeopardizes the patient or may', 'require medical or surgical intervention to prevent one of the outcomes listed above', 'Causes congenital anomaly or birth defect', 'Requires inpatient hospitalization or prolongation of existing hospitalization, unless', 'hospitalization is for:', 'Routine treatment or monitoring of the studied indication, not associated with any', 'deterioration in condition (procedures such as central line placements, paracentesis,', 'pain control)', 'Elective or pre-planned treatment for a pre-existing condition that is unrelated to', 'the indication under study and has not worsened since the start of study drug', 'Treatment on an emergency outpatient basis for an event not fulfilling any of the', 'definitions of a SAE given above and not resulting in hospital admission', ""Social reasons and respite care in the absence of any deterioration in the patient's"", 'general condition', 'Collection of serious adverse events will begin at enrollment and end 30 after the last dose of', 'study treatment or until a new cancer treatment is initiated, whichever happens the soonest.', 'Any death from any cause while a patient is receiving treatment on this protocol or up to 30', 'days after the last dose of protocol treatment, or any death which occurs more than 30 days', 'after protocol treatment has ended but which is felt to be treatment related, must be reported.', 'Toxicities which fall within the definitions listed above must be reported as an SAE regardless', 'if they are felt to be treatment related or not.', 'Page 37 of 52']"
37,page_38,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '16.3 SAE Reporting Requirements', 'A MedWatch 3500A form must be completed to document each observed SAE and submitted', 'to compliance@hci.utah.edu as soon as possible, but no later than 1 working day of first', 'knowledge or notification of event.', 'The Research Compliance Office will appropriately report these SAEs to the DSMC and/or', 'the IRB of record according to the requirements described below:', 'DSMC Notifications:', 'Fatal or life-threatening events meeting the definition of an SAE will be reported within 7', 'calendar days after first knowledge of the event by the investigator.', 'All other events meeting the SAE criteria above will be reported within 15 calendar days', 'after first knowledge of the event by the investigator.', 'Events that meet expedited reporting (serious, unexpected suspected adverse reactions)', 'will be reported to the FDA and IRB, as applicable.', 'IRB Notification:', '1. Events will be submitted to the IRB of record per local guidelines.', '16.4', 'Reporting of Pregnancy', 'Although pregnancy is not considered an adverse event, it is the responsibility of investigators', ""or their designees to report the pregnancy of a male subjects' female partner as an unanticipated"", 'problem involving risk as noted above. Pregnancies or lactation that occurs during the course', 'of the trial or within 30 days of completing the trial must be reported to the DSMC, IRB, and', 'FDA as applicable. All female partners of subjects who become pregnant must be followed to', 'the completion/termination of the pregnancy. Pregnancy outcomes of spontaneous abortion,', 'missed abortion, fetal death, intrauterine death, miscarriage and stillbirth must be reported as', 'serious events.', '16.5', 'Protocol Amendments', 'Any amendments or administrative changes to an IRB approved protocol will not be initiated', 'without submission of an amendment for IRB review and approval.', 'These requirements for approval will in no way prevent any immediate action from being taken', 'by the investigator in the interests of preserving the safety of all subjects included in the trial.', 'Any amendments to the protocol that significantly affect the safety of subjects, scope of the', 'investigation, or the scientific quality of the study are required to submit the amendment for', 'FDA review.', '16.6', 'Protocol Deviations', 'A protocol deviation (or violation) is any departure from the defined procedures and treatment', 'plans as outlined in the protocol version submitted and previously approved by the IRB.', 'Protocol deviations have the potential to place participants at risk and can also undermine the', 'scientific integrity of the study thus jeopardizing the justification for the research. Protocol', 'deviations are unplanned and unintentional events.', 'Page 38 of 52']"
38,page_39,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Because some protocol deviations pose no conceivable threat to participant safety or scientific', 'integrity, reporting is left to the discretion of the PI within the context of the guidelines below.', 'The sponsor requires the prompt reporting to HCI RCO of protocol deviations which are:', 'Exceptions to eligibility criteria.', 'Intended to eliminate apparent immediate hazard to a research participant or', 'Harmful (caused harm to participants or others, or place them at increased risk of', 'harm - including physical, psychological, economic, or social harm), or', 'Possible serious or continued noncompliance', '16.7', 'FDA Annual Reporting', 'This study is IND exempt therefore there are no annual reporting requirements to the FDA.', '16.8', 'Clinical Trials Data Bank', 'The study will be registered on http://clinicaltrials.gov and the NCI CTRP (Clinical Trials', 'Reporting Program) by the Clinical Trials Office.', '16.9', 'Record Keeping', 'Per 21 CFR 312.57, the Investigator records shall be maintained for a period of 2 years', 'following the date a marketing application is approved; or, if no application is filed or the', 'application is not approved, until 2 years after the investigation is discontinued and the FDA', 'is notified.', 'Page 39 of 52']"
39,page_40,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '17', 'BIBLIOGRAPHY', '1. Sweeney CJ, Chen YH, Carducci M, et al: Chemohormonal Therapy in Metastatic Hormone-', 'Sensitive Prostate Cancer. N Engl J Med 373:737-46, 2015', '2.', 'James ND, Sydes MR, Clarke NW, et al: Addition of docetaxel, zoledronic acid, or both to', 'first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from', 'an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163-77,', '2016', '3. Fizazi K, Tran N, Fein L, et al: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive', 'Prostate Cancer. N Engl J Med 377:352-360, 2017', '4.', 'James ND, de Bono JS, Spears MR, et al: Abiraterone for Prostate Cancer Not Previously', 'Treated with Hormone Therapy. N Engl J Med 377:338-351, 2017', '5. Morris MJ, Rumble RB, Basch E, et al: Optimizing Anticancer Therapy in Metastatic Non-', 'Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.', 'J Clin Oncol:JCO2018780619, 2018', '6. STAMPEDE: Addition of docetaxel to first-line long-term hormone therapy in prostate cancer', '(STAMPEDE): Long-term survival, quality-adjusted survival, and cost-effectiveness analysis.', 'J Clin Oncol 36, (suppl 6S; abstr 162), 2018', '7.', 'Chi KN, Protheroe A, Rodriguez-Antolin A, et al: Patient-reported outcomes following', 'abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with', 'newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international,', 'randomised phase 3 trial. Lancet Oncol 19:194-206, 2018', '8. Morgans AK, Chen YH, Sweeney CJ, et al: Quality of Life During Treatment With', 'Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation', 'Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095, 2018', '9. Antonarakis ES, Lu C, Luber B, et al: Clinical Significance of Androgen Receptor Splice', 'Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-', 'Resistant Prostate Cancer Treated With First-a and Second-Line Abiraterone and Enzalutamide.', 'J Clin Oncol 35:2149-2156, 2017', '10. Antonarakis ES, Lu C, Luber B, et al: Androgen Receptor Splice Variant 7 and Efficacy of', 'Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.', 'JAMA Oncol 1:582-91, 2015', '11. Maughan BL, Guedes LB, Boucher K, et al: p53 status in the primary tumor predicts efficacy', 'of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate', 'Cancer Prostatic Dis, 2018', '12. Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after', 'androgen deprivation is a strong independent predictor of survival in new metastatic prostate', 'cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24:3984-', '90, 2006', '13. Harshman LC, Chen YH, Liu G, et al: Seven-Month Prostate-Specific Antigen Is Prognostic', 'in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With', 'or Without Docetaxel. J Clin Oncol 36:376-382, 2018', '14. Esper P, Mo F, Chodak G, et al: Measuring quality of life in men with prostate cancer using', 'the functional assessment of cancer therapy-prostate instrument. Urology 50:920-8, 1997', '15. Calhoun EA, Welshman EE, Chang CH, et al: Psychometric evaluation of the Functional', 'Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx)', 'Page 40 of 52']"
40,page_41,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741-8,', '2003', '16. Cook KF, Jensen SE, Schalet BD, et al: PROMIS measures of pain, fatigue, negative affect,', 'physical function, and social function demonstrated clinical validity across a range of chronic', 'conditions. J Clin Epidemiol 73:89-102, 2016', '17. Tunes da Silva G, Logan BR, Klein JP: Methods for equivalence and noninferiority testing.', 'Biol Blood Marrow Transplant 15:120-7, 2009', '18. Scher HI, Morris MJ, Stadler WM, et al: DOI: 10.1200/JCO.2015.64.2702 Journal of Clinical', 'Oncology 34, no. 12 (April 20 2016) 1402-1418.', 'Page 41 of 52']"
41,page_42,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Appendix A: FACIT Administration Guidelines', 'The FACIT scales are designed for patient self-administration, but can also be administered by', 'interview format. For self-administration, patients should be instructed to read the brief directions', ""at the top of the page. After the patient's correct understanding has been confirmed, he/she should"", 'be encouraged to complete every item in order without skipping any. Some patients may feel that', 'a given question is not applicable to them and will therefore skip the item altogether. Patients', 'should be encouraged to circle the response that is most applicable. If, for example, a patient', 'is not currently receiving any treatment, the patient should circle ""not at all"" to the question ""I am', 'bothered by side effects of treatment.""', 'Page 42 of 52']"
42,page_43,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Appendix B: FACT-P', 'Patient Name:', 'Patient ID:', 'Date:', 'FACT-P (Version 4)', 'Below is a list of statements that other people with your illness have said are important. Please circle', 'or mark one number per line to indicate your response as it applies to the past 7 days.', 'Not', 'A little', 'Some-', 'Quite', 'Very', 'PHYSICAL WELL-BEING', 'at all', 'bit', 'what', 'a bit', 'much', 'GPI', 'I have a lack of energy', '0', '1', '2', '3', '4', 'GP2', 'I have nausea', '0', '1', '2', '3', '4', 'GP3', 'Because of my physical condition, I have trouble', 'meeting the needs of my family', '0', '1', '2', '3', '4', 'GP4', 'I have pain', '0', '1', '2', '3', '4', 'GPS', 'I am bothered by side effects of treatment', '0', '1', '2', '3', '4', 'GP6', 'I feel ill', '0', '1', '2', '3', '4', 'GP7', 'I am forced to spend time in bed', '0', '1', '2', '3', '4', 'SOCIAL/FAMILY WELL-BEING', 'Not', 'A little', 'Some-', 'Quite', 'Very', 'at all', 'bit', 'what', 'a bit', 'much', 'GSI', 'I feel close to my friends', '0', '1', '2', '3', '4', 'GS2', 'I get emotional support from my family', '0', '1', '2', '3', '4', 'GS3', 'I get support from my friends', '0', '1', '2', '3', '4', 'GS4', 'My family has accepted my illness', '0', '1', '2', '3', '4', 'GSS', 'I am satisfied with family communication about my', 'illness', '0', '1', '2', '3', '4', 'GS6', 'I feel close to my partner (or the person who is my main', 'support)', '0', '1', '2', '3', '4', 'Q1', 'Regardless of your current level of sexual activity, please', 'answer the following question. If you prefer not to answer it,', 'please mark this box', 'and go to the next section.', 'GS7', 'I am satisfied with my sex life', '0', '1', '2', '3', '4', 'English (Universal)', '19 November 2007', 'Copyright 1987, 1997', 'Page of 3', 'Page 43 of 52']"
43,page_44,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'FACT-P (Version 4)', 'Please circle or mark one number per line to indicate your response as it applies to the past', '7', 'days.', 'EMOTIONAL WELL-BEING', 'Not', 'A little', 'Some-', 'Quite', 'Very', 'at all', 'bit', 'what', 'a bit', 'much', 'GEI', 'I feel sad', '0', '1', '2', '3', '4', 'GE2', 'I am satisfied with how I am coping with my illness', '0', '1', '2', '3', '4', 'GE3', 'I am losing hope in the fight against my illness', '0', '1', '2', '3', '4', 'GE4', 'I feel nervous', '0', '1', '2', '3', '4', 'GES', 'I worry about dying', '0', '1', '2', '3', '4', 'GE6', 'I worry that my condition will get worse', '0', '1', '2', '3', '4', 'FUNCTIONAL WELL-BEING', 'Not', 'A little', 'Some-', 'Quite', 'Very', 'at all', 'bit', 'what', 'a bit', 'much', 'GFI', 'I am able to work (include work at home)', '0', '1', '2', '3', '4', 'GF2', 'My work (include work at home) is fulfilling', '0', '1', '2', '3', '4', 'GF3', 'I am able to enjoy life', '0', '1', '2', '3', '4', 'GF4', 'I have accepted my illness', '0', '1', '2', '3', '4', 'GFS', 'I am sleeping well', '0', '1', '2', '3', '4', 'GF6', 'I am enjoying the things I usually do for fun', '0', '1', '2', '3', '4', 'GF7', 'I am content with the quality of my life right now', '0', '1', '2', '3', '4', 'Page 44 of 52']"
44,page_45,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'FACT-P (Version 4)', 'Please circle or mark one number per line to indicate your response as it applies to the past 7', 'days.', 'ADDITIONAL CONCERNS', 'Not at', 'A little', 'Some-', 'Quite', 'Very', 'all', 'bit', 'what', 'a bit', 'much', 'C2', 'I am losing weight', '0', '1', '2', '3', '4', 'C6', 'I have a good appetite', '0', '1', '2', '3', '4', 'PI', 'I have aches and pains that bother me', '0', '1', '2', '3', '4', 'P2', 'I have certain parts of my body where I experience pain', '0', '1', '2', '3', '4', 'P3', 'My pain keeps me from doing things I want to do', '0', '1', '2', '3', '4', 'P4', 'I am satisfied with my present comfort level', '0', '1', '2', '3', '4', 'PS', 'I am able to feel like a man', '0', '1', '2', '3', '4', 'P6', 'I have trouble moving my bowels', '0', '1', '2', '3', '4', 'P7', 'I have difficulty urinating', '0', '1', '2', '3', '4', 'BL2', 'I urinate more frequently than usual', '0', '1', '2', '3', '4', 'P8', 'My problems with urinating limit my activities', '0', '1', '2', '3', '4', 'BLS', 'I am able to have and maintain an erection', '0', '1', '2', '3', '4', 'Page 45 of 52']"
45,page_46,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Appendix C: FACT/GOG - NTX', 'Patient Name:', 'Patient ID:', 'Date:', 'FACT/GOG-NTX (Version 4)', 'Please circle or mark one number per line to indicate your response as it applies to the past 7', 'days.', 'ADDITIONAL CONCERNS', 'Not at', 'A little', 'Some-', 'Quite', 'Very', 'all', 'bit', 'what', 'a bit', 'much', 'NTX', 'I have numbness or tingling in my hands', '0', '1', '2', '3', '4', 'NTX', 'I have numbness or tingling in my feet', '0', '1', '2', '3', '4', '2', 'NTX', 'I feel discomfort in my hands', '0', '1', '2', '3', '4', '3', 'NTX', 'I feel discomfort in my feet', '0', '1', '2', '3', '4', 'NTX', 'I have joint pain or muscle cramps', '0', '1', '2', '3', '4', 'H012', 'I feel weak all over', '0', '1', '2', '3', '4', 'NTX', 'I have trouble hearing', '0', '1', '2', '3', '4', '6', 'NTX', '7', 'I get a ringing or buzzing in my ears', '0', '1', '2', '3', '4', 'NTX', 'I have trouble buttoning buttons', '0', '1', '2', '3', '4', '*', 'NTX', 'I have trouble feeling the shape of small objects when', '9', 'they are in my hand', '0', '1', '2', '3', '4', 'Anti', 'I have trouble walking', '0', '1', '2', '3', '4', 'linglish Universal)', '16 Novernber 2007', 'Copyright 1987, 1997', 'Page of 3', 'Page 46 of 52']"
46,page_47,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Appendix D: PROMIS Fatigue', 'Patient Name:', 'Patient ID:', 'Date:', 'Fatigue - Short Form 7a', 'Please respond to each question by marking one box per row.', 'In the past 7 days.', 'Never', 'Rarely', 'Sometimes', 'Often', 'Always', 'FATEXP20', 'How often did you feel tired?', '1', '2', '3', '4', '5', 'How often did you experience extreme', 'FATEMPS', 'exhaustion?', '1', '2', '3', '4', '5', 'How often did you run out of', 'FATEXPII', '1', '2', '3', '4', '5', 'energy?', 'How often did your fatigue limit you at', 'FATIMPIO', 'work (include work at home)?', '1', '2', '3', '4', '5', 'How often were you too tired to think', 'FATIMPJO', '1', '2', '3', '4', '5', 'clearly?', 'How often were you too tired to take a', 'FATIMP21', 'bath or shower?', '1', '2', '3', '4', '5', 'How often did you have enough energy', 'FATIMPHO', '5', '4', '3', '2', '1', 'to exercise strenuously?', '2 May 2016', 'o 2008-2016 PROMIS Health Organization and PROMIS Cooperative Group', 'Page of 1', 'Page 47 of 52']"
47,page_48,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Appendix E: ECOG/KPS Conversion Table', 'ECOG PERFORMANCE STATUS', 'KARNOFSKY PERFORMANCE STATUS', '100-Normal, no complaints; no evidence of', 'disease', '0-Fully active, able to carry on all pre-disease', 'performance without restriction', '90-Able to carry on normal activity; minor signs', 'or symptoms of disease', '80-Normal activity with effort, some signs or', 'symptoms of disease', '1-Restricted in physically strenuous activity but', 'ambulatory and able to carry out work of a light or', 'sedentary nature, e.g., light house work, office work', '70-Cares for self but unable to carry on normal', 'activity or to do active work', '60-Requires occasional assistance but is able', 'to care for most of personal needs', '2-Ambulatory and capable of all selfcare but unable to', 'carry out any work activities; up and about more than 50%', 'of waking hours', '50-Requires considerable assistance and', 'frequent medical care', '40-Disabled; requires special care and', 'assistance', '3-Capable of only limited selfcare; confined to bed or', 'chair more than 50% of waking hours', '30-Severely disabled; hospitalization is', 'indicated although death not imminent', '20-Very ill; hospitalization and active', 'supportive care necessary', '4-Completely disabled; cannot carry on any selfcare;', 'totally confined to bed or chair', '10-Moribund', '5-Dead', '0-Dead', '*Karnofsky D, Burchenal J, The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C, ed.', 'Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:191-205.', '**Zubrod C, et al. Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of', 'nitrogen mustard and thiophosphoramide. Journal of Chronic Diseases; 1960:11:7-33.', 'Page 48 of 52']"
48,page_49,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Appendix F: Overall Treatment Utility Form', 'Patient Name:', 'Patient ID:', 'Date:', 'Overall Treatment Utility (OTU)', 'OTU is a novel clinical outcome measure incorporating objective and subjective measures of anticancer', 'efficacy, tolerability and acceptability, assessed 12 weeks after starting treatment and condensed into a', 'simple 3-point score.', 'OTU may be regarded as asking the clinician: ""With the benefit of hindsight, are you glad you gave this', 'treatment?"" and asking the patient: ""With the benefit of hindsight, are you glad you received it?"": OTU', 'is scored as good, intermediate or poor, corresponding to ""yes"", ""uncertain"" or ""no"" replies to these', 'questions.', 'To score OTU, the patient is assessed 12 weeks after randomisation (acceptable window 10-14 weeks),', 'using the following criteria:', '1. Clinical benefit? Categorised as:', 'a. Both radiologically progression-free (RECIST response or stable disease)', 'and no clinical deterioration², as assessed by treating consultant', 'b. Either radiological progression (RECIST progressive disease)', 'or clinical deterioration, as assessed by treating consultant', '2. Tolerable and acceptable? Categorised as:', 'a. All of the following:', 'no SAE or SUSAR attributed to treatment', 'no episodes of grade >3 non-haematological toxicity', '2', 'patient response to LHA Q37 (""How much has your treatment interfered with your', 'normal daily activities?"") is not ""Very much""', 'patient response to LHA² Q38 (""How worthwhile do you think your treatment has', 'been?"") is not ""Not at all""', 'b. Any of the following:', 'an SAE or SUSAR attributed to treatment', 'an episode of grade >3 non-haematological toxicity', 'patient response to LHA² Q37 (""How much has your treatment interfered with your', 'normal daily activities?"") is ""Very much""', 'patient response to LHA² Q38 (""How worthwhile do you think your treatment has', 'been?"") is ""Not at all""', 'Scoring:', 'Good OTU:', 'Patient is alive and scores 1a/2a', 'Intermediate OTU:', 'Patient is alive and scores 1a/2b or 1b/2a', 'Poor OTU:', 'Patient is alive and scores 1b/2b, or patient is dead', '1 Clinical deterioration = clear clinical evidence of cancer progression which has not been confirmed radiologically.', '2 LHA = Limited Heath Assessment Please see webappendix pages 9-13 for full details of the LHA.', 'Investigator Signature', 'Date', 'Page 49 of 52']"
49,page_50,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Appendix G: Was It Worth It Questionnaire', 'To be completed by Physician, Nurse, or CRA:', 'Patient Name:', 'Date:', 'Patient Number:', 'Participating in a clinical trial / research study is a personal choice and an individual experience.', 'We would like to get your feedback on your experience in this research study.', 'Directions: Please answer each question by circling Y (for yes), N (for no), or U (for uncertain).', '1. Was it worthwhile for you to participate in this research study?', 'Y', 'N', 'U', '2. If you had to do it over, would you participate in this research study again?', 'Y', 'N', 'U', '3. Would you recommend participating in this research study to others?', 'Y', 'N', 'U', '4. Overall, did your quality of life change by participating in this research study? (circle one response)', 'It improved', 'It stayed the same', 'It got worse', '5. Overall how was your experience participating in this research study? (circle one response)', 'Better than I expected', 'The same as I expected', 'Worse than I expected', '6. If there was one thing that could have been done to improve your experience in this research study,', 'what would it be?', '7. Would you like to talk to someone about your concerns?', 'Yes', 'No', '(circle one response)', 'Page 50 of 52']"
50,page_51,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Appendix H: End of Study Evaluation Form', 'Patient Name:', 'Patient ID:', 'Date:', 'Which one of the following phrases best describes you at this time? (Mark one with an X.)', 'Normal, no complaints, no symptoms of disease', 'Able to carry on normal activity, minor symptoms of disease', 'Normal activity with effort, some symptoms of disease', 'Care for self, unable to carry on normal activity or do active work', 'Require occasional assistance but able to care for most of personal needs', 'Require considerable assistance for personal care', 'Disabled, require special care and assistance', 'Severely disabled, require continuous nursing care', 'Page 51 of 52']"
51,page_52,"['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Appendix I: Extent of Metastases Form', 'Patient Name:', 'Patient ID:', 'Date:', 'For purposes of this study, extent of metastases will be defined in accordance with the', 'CHAARTED trial. \'High Volume\' disease is defined as ""Yes\' to question 1. Also patient may', 'qualify as ""High Volume\' by answering ""Yes\' to question 2 and 3. Otherwise, patients are', ""defined as 'Low Volume'."", '1. Presence of visceral metastases (Y/N):', '2. > 4 Bone lesions (Y/N):', '3. >1 bone lesion outside of the vertebral column and pelvis (Y/N):', 'Extent of disease determination (High/Low Volume):', 'Investigator Signature', 'Date', 'Page 52 of 52']"
